Study Confirms Cannabinoids Relieve MS Spasticity
A meta-analysis of 31 studies suggests that cannabinoids, particularly nabiximols, can effectively reduce spasticity in multiple sclerosis (MS) patients, though responses vary. While nabiximols is approved in Canada and Europe for MS spasticity, the safety and efficacy of cannabis-based treatments remain unclear, necessitating larger studies. The analysis found significant reductions in spasticity using the MS spasticity Numerical Rating Scale and the Ashworth Scale, but results differed due to varying study criteria and definitions.
